In Vitro: Bisdemethoxycurcumin (1-10 μM; 5 h) significantly inhibits HT1080 cancer cell invasion, but does not affect cell migration. Bisdemethoxycurcumin (1-10 μM; 24 h) inhibits the secret of MMP-9 in HT1080 cells, and affects cancer cell invasion and metastasis. Bisdemethoxycurcumin (5-50 μM; 24 h) Bisdemethoxycurcumin (5-50 μM; 24 h) significantly inhibits collagenase, MMP-2 and MMP-9 activities in HT1080, but does not inhibit uPA activity. Bisdemethoxycurcumin (25 μM; 18 h, 24 h) arrests cell cycle at G1 phase, and (5-25 μM) inhibits the expression of C/EBPα and PPARγ in 3T3-L1 adipocyte 270 differentiation. Bisdemethoxycurcumin inhibits lipid accumulation in adipocytes, primarily by attenuating mitotic clonal expansion (MCE) to inhibit early lipogenesis.
In Vivo: Bisdemethoxycurcumin (0.5% in diet; 15 weeks) significantly reduces both final body weight and body weight gain in HFD-induced obese mice.